Category: Cardiovascular Disease

ACC/AHA Issue Report for CV and Non-CV Complications of COVID-19

June 30, 2022

The American College of Cardiology/American Heart Association ​​Task Force on Clinical Data Standards published a report June 23 listing and defining key data elements related to cardiovascular and noncardiovascular complications of COVID-19. 

ACC 2022: Update on Mavacamten for Obstructive Hypertrophic Cardiomyopathy

April 29, 2022

Mavacamten had a big week at the American College of Cardiology 2022 Scientific Sessions, with two positive Late-Breaking Clinical Trial sessions.  Mavacamten is an investigational, ​first-in-class, cardiac-specific myosin inhibitor that reduces the number of available actin-myosin cross-bridges and thus decreases excessive myocardial contractility.

ACC 2022: Novel Gene-Silencing Therapy Cuts Lp(a) by 98%

April 11, 2022

Among the top-notch research presented at the American College of Cardiology 2022 Scientific Sessions was a small phase 1 trial that demonstrated big potential for a therapeutic that will lower lipoprotein [Lp(a)] and reduce atherosclerotic risk. 

FDA Approves Empagliflozin for HFpEF

March 3, 2022

FDA Approves Empagliflozin for Heart Failure with Preserved Ejection Fraction. With this latest FDA approval, it’s time to get up to date on the newest treatments for heart failure. K2P is here to help.

Rethinking Rhythm Control in AF: Sooner Rather than Later?

September 8, 2020

One of the several noteworthy trials presented at the virtual ESC Congress was the EAST-AFNET 4NET 4 trial, which was published concurrently in the New England Journal of Medicine. 

Early News from the Virtual ESC Congress EXPLORER-HM

August 31, 2020

Lacopo Olivotto, MD, presented the results of the EXPLORER-HCM trial, which examined mavacamten as an alternative to surgical or catheter-based interventions to treat obstructive hypertrophic cardiomyopathy (HCM).

Tips to Address the Challenges of non-COVID Care in the Time of a Pandemic

August 10, 2020

In addition to managing the enormous burden of COVID-19 infection and mortality, clinicians are also charged with how we can best provide ongoing regular care for non-COVID patients.

COVID-19: Impact on Cardiovascular Disease Care, Lifelong Learning, and Research

July 27, 2020

In a special report last week, the European Heart Journal spoke to cardiovascular disease (CVD) thought leaders across the globe to gather their insights on the impact of the COVID-19 pandemic on cardiovascular care.

1 of 1